Coherus Oncology, Inc. (CHRS) vs MediWound Ltd. (MDWD)

Coherus Oncology, Inc. and MediWound Ltd. are both Biotechnology companies. Coherus Oncology, Inc. and MediWound Ltd. are of similar size ($183.9M and $178.6M). Coherus Oncology, Inc. grew revenue faster over the last twelve months: 61.0% against −40.3%. MediWound Ltd. has the higher net margin (−170.1% vs −259.4%) and the lower return on invested capital (−6,551.8% vs 0.00%). Across the 19 metrics below, MediWound Ltd. leads on 10 and Coherus Oncology, Inc. on 9.

Valuation

Metric CHRS MDWD Biotechnology median
P/E n/m n/m 7.88
P/S 3.43 15.04 11.47
P/B 2.88 5.01 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 5.53 12.14 10.73
Earnings yield (91.15%) (11.55%) (28.84%)
Free cash flow yield (106.88%) (16.01%) (23.03%)

Profitability

Metric CHRS MDWD Biotechnology median
Gross margin 68.94% 15.46% 65.16%
Operating margin (311.56%) (267.75%) 0.00%
Net margin (259.41%) (170.10%) 0.00%
Free cash flow margin (365.22%) (240.47%) 0.00%
Return on equity (146.27%) (75.42%) (57.72%)
Return on assets (41.90%) (29.06%) (49.22%)
Return on invested capital 0.00% (6,551.77%) 0.00%

Growth

Metric CHRS MDWD Biotechnology median
Revenue growth (TTM) 61.00% (40.26%) 5.64%
EPS growth (last fiscal year) 472.00% 30.69% —
Revenue growth, 5-year CAGR (38.41%) (4.87%) 8.40%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS MDWD Biotechnology median
Debt to equity 0.61 0.00 0.00
Current ratio 1.77 2.32 4.73
Net debt to EBITDA 0.76 2.27 0.96

Dividend

Metric CHRS MDWD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CHRS MDWD Biotechnology median
Market cap 183.86m 178.55m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack